Martin Stockley

This inventor holds 34 USPTO granted patents and 11 published patent applications, plus 5 CIPO patents and 25 EPO patents, primarily in Cancer Treatment Compounds. Top assignees: Mission Therapeutics Limited, Cancer Research Technology Limited, Artios Pharma Limited. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin Stockley. Retrieved from https://idiyas.com/inventor/martin-stockley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 11)

% Patents Active = 97.1

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 25 (Patent Applications = 35)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Lordshill, GB (2012)
Cambridge, GB (2018 - 2024)

Company Filing History:

29 out of 34

Mission Therapeutics Limited

patents

2 out of 268

Cancer Research Technology Limited

patents

1 out of 1

Artios Pharma Limited

patent

4. 1 out of 1

Missions Therapeutics Limited

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

USP30 Inhibitors

DUB Inhibitors

Cancer Treatment

Cyanopyrrolidines

Heterocyclic Compounds

Autotaxin Inhibitors

Pyrrolidine Derivatives

Deubiquitylating Enzymes

Cyano-Substituted Compounds

Spiro-Condensed Derivatives

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655152 - 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis (2026-06-16),

2. 12637426 - 1-cyano-pyrrolidine compounds as USP30 inhibitors (2026-05-26),

3. 12358886 - Heterocyclic compounds for use in the treatment of cancer (2025-07-15),

4. 11993595 - Compounds (2024-05-28),

5. 11958833 - Compounds (2024-04-16),

6. 11945797 - 1-cyano-pyrrolidine derivatives as dub inhibitors (2024-04-02),

7. 11472798 - Compounds (2022-10-18),

8. 11453666 - Autotaxin inhibitory compounds (2022-09-27),

9. 11414402 - Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors (2022-08-16),

10. 11390584 - 1-cyano-pyrrolidine compounds as USP30 inhibitors (2022-07-19),

11. 11370784 - Cyano-substituted heterocycles with activity as inhibitors of USP30 (2022-06-28),

12. 11352339 - 1-cyano-pyrrolidine derivatives as DUB inhibitors (2022-06-07),

13. 11319287 - Cyanopyrrolidines as dub inhibitors for the treatment of cancer (2022-05-03),

14. 11306096 - 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer (2022-04-19),

15. 11236092 - Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors (2022-02-01),

Title: Inventor Martin Stockley - Revolutionizing Technology in Cambridge

Introduction: Martin Stockley is a visionary inventor based in Cambridge, United Kingdom, known for his groundbreaking contributions to the field of technology.

Latest Patents: Martin Stockley holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Martin Stockley has worked with leading research institutions and tech companies, consistently pushing the boundaries of what is possible in the world of innovation.

Collaborations: Throughout his career, Martin Stockley has collaborated with top universities, multinational companies, and research institutions, fostering a culture of creativity and excellence in all his projects.

Conclusion: Martin Stockley's passion for innovation and his relentless drive to create a better future through technology make him a true pioneer in the field of inventions.

Profile summary based on public USPTO records.